If you look at slide 15 of their March BIO-Europe presentation, they showed plans to perform a Phase 1b/2a trial of ZEN-3694 in combination with abiraterone in mCRPC as a separate arm in current study with protocol modification. So even though they started with the ZEN-3694/enzalutamide combo for those patients that have developed resistance to abiraterone or enzalutamide, it appears that are going to also investigate combo ZEN-3694/abiraterone too.